In this interview, Christian Roghi explores the manufacturing, quality control and regulatory challenges facing living medicines; from microbiome therapeutics to phage therapies and engineered bacteria, he reveals what is needed to bring these products to market at scale.
Alex Gauthier at Novartis reviews practical toxicological strategies for managing late-stage nitrosamine drug substance-related impurities (NDSRIs) while maintaining patient safety and development timelines.
Mike King at IQVIA reveals why digital quality documentation is deemed a key enabler in advanced therapy sectors, increasingly influencing how sponsors select manufacturers.
Discover the key technologies, risk mitigation strategies and development considerations shaping modern pharmaceutical formulation — from early-stage selection through to commercial-scale manufacturing.
The FDA has accepted a second investigational new drug (IND) application under Evotec and Bristol Myers Squibb’s strategic protein degradation partnership, with the candidate expected to enter Phase I trials in 2027.
Calla Lily Clinical Care has secured a £700k Innovate UK grant to adapt its intravaginal drug delivery platform for live biotherapeutics and probiotics targeting vaginal microbiome health.
The European Commission has approved olezarsen for adults with severe hypertriglyceridaemia, following Phase 3 results showing reduced triglyceride levels and fewer acute pancreatitis events.
Laverock Therapeutics appoints new leadership team as it prepares to advance its CAR-T programmes towards clinical development.
Explore the implementation of PUPSIT and the infrastructure, processes and expertise needed to support sterile filtration compliance under EU GMP Annex 1.
In this whitepaper, explore how human pharmacokinetic data can guide formulation decisions, minimise development risk and help teams select the simplest viable approach for poorly soluble molecules.
In this interview, Christian Roghi explores the manufacturing, quality control and regulatory challenges facing living medicines; from microbiome therapeutics to phage therapies and engineered bacteria, he reveals what is needed to bring these products to market at scale.
Jennifer Gattari of Pfizer CentreOne discusses how patient needs, evolving delivery formats and emerging manufacturing trends are shaping the pharmaceutical industry, from oral solid dose products to sterile injectables.